Durvalumab - Latest Advances

Timing of Durvalumab Consolidation and Survival in Non-Small Cell Lung Cancer: A Population-Based Analysis.

Journal: JCO oncology practice

Published: December 10, 2025

Thymus Composition Predicts Pneumonitis Risk in Lung Cancer Therapy.

Journal: medRxiv : the preprint server for health sciences

Published: November 24, 2025

Thymus Composition, Disease Control, and Toxicity in Locally Advanced Lung Cancer.

Journal: medRxiv : the preprint server for health sciences

Published: November 24, 2025

LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers.

Journal: Future oncology (London, England)

Published: November 24, 2025

Preoperative Immunotherapy in Oncology.

Journal: Deutsches Arzteblatt international

Published: November 20, 2025

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer.

Journal: Research square

Published: November 19, 2025

Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.

Journal: British journal of cancer

Published: November 11, 2025

Tremelimumab Plus Durvalumab in Advanced Hepatocellular Carcinoma Treatment: A Pharmacovigilance Comparative Analysis Between Eudravigilance and HIMALAYA Study.

Journal: Hospital pharmacy

Published: November 04, 2025

Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials.

Journal: Immunotherapy

Published: November 01, 2025

Letter to the Editor: Durvalumab Consolidation in PD-L1 Negative Stage III NSCLC: Real-World Evidence Beyond Regulatory Boundaries.

Journal: Clinical lung cancer

Published: October 27, 2025

EGFR‒Positive Stage ⅢB NSCLC in Which Durvalumab and Osimertinib Were Ineffective after CCRT-A Case Report.

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: October 27, 2025

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for bladder cancer, panitumumab plus sotorasib for colorectal cancer, and vorasidenib for glioma.

Journal: International journal of clinical oncology

Published: October 25, 2025

Filters

Timing of Durvalumab Consolidation and Survival in Non-Small Cell Lung Cancer: A Population-Based Analysis.

Timing of Durvalumab Consolidation and Survival in Non-Small Cell Lung Cancer: A Population-Based Analysis.

Thymus Composition Predicts Pneumonitis Risk in Lung Cancer Therapy.

Thymus Composition Predicts Pneumonitis Risk in Lung Cancer Therapy.

Thymus Composition, Disease Control, and Toxicity in Locally Advanced Lung Cancer.

Thymus Composition, Disease Control, and Toxicity in Locally Advanced Lung Cancer.

LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers.

LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers.

Preoperative Immunotherapy in Oncology.

Preoperative Immunotherapy in Oncology.

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer.

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer.

Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.

Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.

Tremelimumab Plus Durvalumab in Advanced Hepatocellular Carcinoma Treatment: A Pharmacovigilance Comparative Analysis Between Eudravigilance and HIMALAYA Study.

Tremelimumab Plus Durvalumab in Advanced Hepatocellular Carcinoma Treatment: A Pharmacovigilance Comparative Analysis Between Eudravigilance and HIMALAYA Study.

Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials.

Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials.

Letter to the Editor: Durvalumab Consolidation in PD-L1 Negative Stage III NSCLC: Real-World Evidence Beyond Regulatory Boundaries.

Letter to the Editor: Durvalumab Consolidation in PD-L1 Negative Stage III NSCLC: Real-World Evidence Beyond Regulatory Boundaries.

EGFR‒Positive Stage ⅢB NSCLC in Which Durvalumab and Osimertinib Were Ineffective after CCRT-A Case Report.

EGFR‒Positive Stage ⅢB NSCLC in Which Durvalumab and Osimertinib Were Ineffective after CCRT-A Case Report.